Wei Lu, PhD, Professor

Chairman of Department of Pharmaceutics,

School of Pharmaceutical Science

Director of Peking University/Pfizer Pharmacometrics Education Center

Peking University Peking University

        Got his Bachelor and PhD degree from Beijing College of Traditional Chinese Medicine (China, 1982) and Toyama Medical and Pharmaceutical University (Japan, 1988), respectively. Joint Beijing Medical University School of Pharmaceutical Science (current Peking University School of Pharmaceutical Science) at 1988. Visited and worked in the university and industry in the United States in the field of population pharmacokinetics and pharmacokinetics/pharmacodynamics modeling and simulation between 1996 and 2003. Current the Professor, Chair of Department of Pharmaceutics, Member of Academic Committee of Peking University Health Science Center, Director of Peking University/Pfizer Pharmacometrics Education Center, and the Vice President of Mathematic Pharmacology Professional Committee of China.

Research interests

   Modeling and Simulation (M&S) in Population Pharmacokinetics (PopPK)

Ø  New drug evaluation (M&S)

Ø  Clinical pharmacology (TDM)

   Modeling and Simulation (M&S) in Pharmacokinetics/pharmacodynamics (PKPD)

Ø  Response surface model for DDI

Ø  Mechanistic PKPD

Ø  PKPD with continuing and categorical/count data

Courses Opened

   Biopharmaceutics and Pharmacokinetics

   Population Pharmacokinetics and Pharmacokinetics/pharmacodynamics Modeling and Simulation

Publications (Part)

 L. Li, W. Lu et al., Mechanism-based Pharmacokinetic/Pharmacodynamic Model for CYP3A1/2 Induction by Dexamethasone in Rats, Acta Pharmacologica Sinica, 2011, accepted

 D.W. Shang, W. Lu and T.Y. Zhou et al., Simultaneous determination of nitrendipine and hydrochlorothiazide in spontaneously hypertensive rat plasma using HPLC with on-line solid-phase extraction, International Journal of Clinical Pharmacology & Therapeutics, 2011, accepted

 Y. Zhao, W. Lu et al., Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients, Chinese Medical Journal 122: 291-5, 2009

 L.P. Zhang, W. Lu et al., Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation, Chin Med J (Engl). 122: 1032-8, 2009

 Y.Q. Zhang and W. Lu et al., Development of a Sensitive High-Performance Liquid Chromatographic Method with Simple Extraction for Simultaneous Determination of Huperzine A and Huperzine B in the Species Containing Lycopodium Alkaloids, J. of AOAC International，92(4): 1060-3, 2009

 D. Li, W. Lu et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients, Journal of Clinical Pharmacy and Therapeutics, 32: 505–15, 2007

 M.G. Shou, W. Lu et al., Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey, European Journal of Pharmaceutical Sciences, 26: 151–61, 2005

 K.H. Wu, W. Lu et al., Population Pharmacokinetics of Cyclosporine in Clinical Renal Transplant Patients, Drug Metabolism and Dispositio, 33: 1268–75, 2005

 W. Lu, J. Bailey, Reliability of Pharmacodynamic Analysis by Logistic Regression: Mixed Effects Modeling, Anesthesiology, 99: 1255-62, 2003